Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Genitourinary 1CNS 1

Conditions

Pheochromocytoma 2Paraganglioma 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Doxazosin × Endocrine × Clear all
NCT01379898 2024-09-19

PRESCRIPT

University Medical Center Groningen

Phase 4 Completed
134 enrolled
Endocrine

Pheochromocytoma

NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

University of California, Los Angeles

Phase 3 Completed
39 enrolled 8 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡